Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EB04
|
| gptkbp:brand |
gptkb:Tagrisso
|
| gptkbp:CASNumber |
1421373-65-0
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:halfLife |
48 hours
|
| gptkbp:hasMolecularFormula |
C28H33N7O2•CH4O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
osimertinib mesylate
|
| gptkbp:indication |
EGFR T790M mutation-positive NSCLC
|
| gptkbp:KEGGID |
D10568
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:EGFR_tyrosine_kinase_inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
gptkb:DB09330
CHEMBL3185146 71512363 |
| gptkbp:sideEffect |
diarrhea
rash dry skin nail toxicity |
| gptkbp:target |
gptkb:epidermal_growth_factor_receptor
|
| gptkbp:UNII |
6Y7T8G377Q
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Tagrisso
|
| gptkbp:bfsLayer |
6
|